Article
Oncology
Karan Pandya, Michael J. Overman, Pat Gulhati
Summary: Small bowel adenocarcinoma (SBA) is a rare malignancy with poor prognosis. Over 90% of SBA tumors have targetable genetic alterations. Molecular analysis is critical for identifying these alterations and guiding treatment decisions. SBA is a molecularly unique intestinal cancer, with distinct genomic alterations predictive of response to targeted therapy and immunotherapy.
Review
Oncology
Anthony Turpin, Mehdi El Amrani, Aziz Zaanan
Summary: Small bowel adenocarcinoma is a rare and aggressive disease that requires peri-operative treatment. Due to its rarity, there is limited data on its treatment, and recommendations are mostly based on expert agreements or analogies to colon cancer management.
Review
Oncology
Divya Khosla, Treshita Dey, Renu Madan, Rahul Gupta, Shikha Goyal, Narendra Kumar, Rakesh Kapoor
Summary: Small bowel adenocarcinoma is a rare malignancy of the gastrointestinal tract with vague symptoms and diagnostic challenges, leading to delayed treatment and poor prognosis. Advances in imaging technology have improved early and accurate diagnosis. Surgery is the preferred treatment followed by adjuvant therapy, but there are no strict treatment guidelines available. Prognosis for SBA is better than gastric carcinoma but worse than colorectal carcinoma. Further research is needed to understand the molecular characteristics and tumor pathogenesis.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Ya'nan Zhen, Jianqi Li, Ruogu Wang, Shoutang Lu, Yongshun Zhou, Ruixue Xiao
Summary: This case highlights the rare occurrence of metachronous small bowel adenocarcinoma following resection of rectal adenocarcinoma. Clinicians should be alert to the possibility of small bowel adenocarcinoma in high-risk patients with corresponding symptoms, and further examinations are crucial for accurate diagnosis. Early screening for small bowel adenocarcinoma may lead to better prognosis for patients.
Article
Surgery
Yanmei Gu, Haixiao Deng, Daijun Wang, Yumin Li
Summary: The metastasis pattern significantly impacts the long-term survival of patients with SBA. A prognostic nomogram considering various factors, including age, tumor grade, T stage, N stage, surgery, lymph node retrieval, and chemotherapy, was established, with the metastasis pattern being the most influential factor for survival prediction.
FRONTIERS IN SURGERY
(2021)
Article
Oncology
Jinju Sun, Kaijun Liu, Haipeng Tong, Huan Liu, Xiaoguang Li, Yi Luo, Yang Li, Yun Yao, Rongbing Jin, Jingqin Fang, Xiao Chen
Summary: The study investigated the potential of CT imaging features and texture analysis to distinguish bronchiolar adenoma from adenocarcinoma in situ/minimally invasive adenocarcinoma, showing that texture analysis can effectively improve the efficacy of thin-section unenhanced CT for discriminating between the two lesions, with a potential clinical value.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Wuming Zhang, Xianqin Hu, Zhikang Chen, Chen Lai
Summary: This study reports a case of synchronous small bowel adenocarcinoma (SAB) accompanied by gastrointestinal stromal tumor (GIST) and gangliocytoma in a patient with neurofibromatosis type 1 (NF-1). Genetic testing revealed a novel germline NF1 mutation and a PMS2 mutation, and the possible relationship between them in promoting tumorigenesis was explored. The results suggest the presence of multiple gastrointestinal tumors in NF1 patients, and genetic testing can provide more efficient guidance for postoperative treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pathology
Chad Vanderbilt, Thomas Brenn, Andrea P. Moy, Gordon Harloe, Charlotte Ariyan, Edward Athanasian, Klaus J. Busam
Summary: Digital papillary adenocarcinoma (DPAC) is a rare tumor of sweat gland origin that preferentially affects the digits and has the potential to metastasize. This study confirms the association of HPV42 with DPAC tumor cells through in situ hybridization, suggesting the potential diagnostic utility of the assay.
Article
Multidisciplinary Sciences
Jinggao Feng, Xiayu Tang, Liusong Song, Zhipeng Zhou, Yuan Jiang, Yao Huang
Summary: This study identified four potential target genes related to the pathogenesis of small bowel adenocarcinoma and established a robust risk prediction model. Additionally, the infiltration of immune cells and activation of immune pathways were confirmed in small bowel adenocarcinoma.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Thomas Aparicio, Atanas Pachev, Pierre Laurent-Puig, Magali Svrcek
Summary: Small bowel adenocarcinoma is a rare tumor with increasing incidence. Diagnosis is often obtained at an advanced stage and prognosis is poor. There is no clearly identified environmental risk factor, but it is associated with certain predisposing diseases.
Article
Gastroenterology & Hepatology
David J. M. Tate, Maria Eva Argenziano, John Anderson, Pradeep Bhandari, Ivo Boskoski, Marek Bugajski, Lobke Desomer, Steven J. Heitman, Hiroshi Kashida, Vladimir Kriazhov, Ralph R. T. Lee, Ivan Lyutakov, Pedro Pimentel-Nunes, Liseth Rivero-Sanchez, Siwan Thomas-Gibson, Henrik Thorlacius, Michael J. Bourke, Tony C. Tham, Raf Bisschops
Summary: Endoscopic mucosal resection (EMR) is the standard treatment for high-risk large colorectal polyps. Training should include basic skills in diagnostic colonoscopy, polypectomy, and endoscopic hemostasis. Formal training courses and supervised in vivo training are recommended. EMR training units should have specific processes in place to support and facilitate training. Trained practitioners should have theoretical knowledge and skills in assessing risk, interpreting difficulty, deciding on en bloc or piecemeal resection, managing adverse events, and communicating with patients.
Article
Oncology
J. Yu, E. Refsum, V Perrin, L. M. Helsingen, P. Wieszczy, M. Loberg, M. Bretthauer, H. O. Adami, W. Ye, J. Blom, M. Kalager
Summary: This population-based cohort study found that patients with inflammatory bowel disease (IBD) have a higher risk of small bowel adenocarcinoma and neuroendocrine tumors. Specifically, patients with Crohn's disease (CD) had an eightfold increased risk of small bowel adenocarcinoma, patients with both UC and CD had about a twofold increased risk of neuroendocrine tumors, and patients with UC had a twofold increased risk of small bowel adenocarcinoma. However, due to the small absolute excess cancer risk, active surveillance to diagnose small intestinal cancer early may not be cost-effective.
ANNALS OF ONCOLOGY
(2022)
Review
Oncology
Paola Di Nardo, Silvio Ken Garattini, Elena Torrisi, Valentina Fanotto, Gianmaria Miolo, Angela Buonadonna, Fabio Puglisi
Summary: This systematic review aimed to identify the optimal treatment for small bowel adenocarcinoma based on the available evidence. The review found limited evidence supporting the use of chemotherapy doublets as a first-line treatment, while there is not enough evidence to support the use of biological agents. Immunotherapy showed promising results in selected patients. Overall, small bowel adenocarcinoma is a rare disease with scarce evidence for treatment options.
Review
Biochemistry & Molecular Biology
Alessandro Vanoli, Federica Grillo, Daniela Furlan, Giovanni Arpa, Oneda Grami, Camilla Guerini, Roberta Riboni, Luca Mastracci, Antonio Di Sabatino
Summary: The broader use of gastrointestinal endoscopic procedures has resulted in an increased detection of small intestinal precancerous and cancerous epithelial lesions, which are often associated with hereditary tumor syndromes and immune-related disorders. These lesions exhibit different molecular pathogenetic mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
D. Bhamidipati, A. Colina, H. Hwang, H. Wang, M. Katz, K. Fournier, V Serpas, J. Thomas, R. Sun, R. A. Wolff, K. Raghav, M. J. Overman
Summary: Metastasectomy may improve overall survival in selected patients with SBA; Fluoropyrimidine plus platinum is a common first-line chemotherapy option; Immune therapy is effective for deficient mismatch repair (dMMR) SBA.